Frequent factor II G20210A mutation in idiopathic portal vein thrombosis

被引:86
作者
Chamouard, P [1 ]
Pencreach, E
Maloisel, F
Grunebaum, L
Ardizzone, JF
Meyer, A
Gaub, MP
Goetz, J
Baumann, R
Uring-Lambert, S
Levy, S
Dufour, P
Hauptmann, G
Oudet, P
机构
[1] Hop Hautepierre, Serv Hepatogastroenterol & Assistance Nutrit, F-67098 Strasbourg, France
[2] Hop Hautepierre, Lab Immunol & Hematol, F-67098 Strasbourg, France
[3] Hop Hautepierre, Serv Oncohematol, F-67098 Strasbourg, France
[4] Hop Hautepierre, Biochim Lab, Unite Fonct Biol Mol, Strasbourg, France
关键词
D O I
10.1016/S0016-5085(99)70238-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Despite extensive investigations of portal vein thrombosis, no underlying cause is identifiable in up to 30% of patients. A recently described mutation of the prothrombin gene at nucleotide position 20210 is associated with history of venous thrombosis and was assessed in this study. Methods: We compared the frequency of factor II G20210A and factor V G1691A (factor V Leiden) mutations in 10 patients with idiopathic portal vein thrombosis, 10 patients with nonidiopathic portal vein thrombosis, 60 patients with deep vein thrombosis of the legs, and 42 control subjects. Results: The frequency of factor II G20210A mutation was increased in patients with idiopathic portal vein thrombosis (40.0%; confidence interval, 3.1%-76.9%) compared with controls (4.8%; confidence interval, 0%-11.5%) or patients with nonidiopathic portal vein thrombosis or deep vein thrombosis (P = 0.0001). In contrast, the frequency of the factor V G1691A mutation was similar in subjects with portal vein thrombosis and in controls but was increased in patients with deep vein thrombosis (P = 0.0001). Conclusions: The factor II G20210A mutation is frequent in patients with idiopathic portal vein thrombosis and should therefore be assessed under this circumstance.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 27 条
[1]  
BAROSI G, 1991, CANCER, V68, P2310, DOI 10.1002/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO
[2]  
2-2
[3]  
BERLIN NI, 1986, SEMIN HEMATOL, V23, P131
[4]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[5]   PROTHROMBIN SALAKTA - AN ABNORMAL PROTHROMBIN CHARACTERIZED BY A DEFECT IN THE ACTIVE-SITE OF THROMBIN [J].
BEZEAUD, A ;
DROUET, L ;
SORIA, C ;
GUILLIN, MC .
THROMBOSIS RESEARCH, 1984, 34 (06) :507-518
[6]  
CARDOT F, 1992, GASTROEN CLIN BIOL, V16, P644
[7]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[8]   Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients [J].
De Stefano, V ;
Chiusolo, P ;
Paciaroni, K ;
Casorelli, I ;
Rossi, E ;
Molinari, F ;
Servidei, S ;
Tonali, PA ;
Leone, G .
BLOOD, 1998, 91 (10) :3562-3565
[9]  
Denninger MH, 1997, THROMB HAEMOSTASIS, V78, P1297
[10]   PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ASSOCIATED WITH HEPATIC AND PORTAL VENOUS THROMBOSIS [J].
GROSSMAN, JA ;
MCDERMOTT, WV .
AMERICAN JOURNAL OF SURGERY, 1974, 127 (06) :733-736